COSM Cosmos Health Inc.
Price Chart
Executive Summary
Cosmos Health, through its subsidiary Cana Laboratories, signed a five-year contract manufacturing agreement with Pharmex S.A. to produce three pharmaceutical products totaling 2.86 million units. No financial terms were disclosed, but the deal supports higher utilization of its EU-GMP facility and adds recurring revenue visibility.
Actionable Insight
The contract provides recurring revenue visibility for Cana's EU-GMP facility. Monitor for additional contract announcements and future financial disclosures to assess revenue contribution.
Key Facts
- Five-year contract manufacturing agreement with Pharmex S.A. for three products: BETAFUSIN, BOTAFEX, and BUDESODERM.
- Combined volumes of approximately 2.86 million units over the five-year term.
- Manufacturing will occur at Cana Laboratories' EU-GMP-licensed, EMA-certified facility.
- Financial terms of the agreement were not disclosed.
Financial Impact
Five-year contract manufacturing agreement for 2.86 million units; financial terms not disclosed.
Risk Factors
- No financial terms disclosed; contract may be low-margin.
- Pharmex may not meet volume commitments.
- Concentration risk if a few contracts dominate manufacturing revenue.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313521 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 17, 2026
3d ago
|
Press Release
| $0.2417 $0.2129 | ▼ −11.92% | ▼ −12.70% | $0.2130 (−11.87%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 10, 2026
10d ago
|
Press Release
| $0.2281 $0.2060 | ▼ −9.69% | ▼ −11.39% | $0.2130 (−6.62%) |
|
Jun 9, 2026
11d ago
|
Press Release
| $0.2233 $0.2281 | ▲ +2.15% | ▲ +3.73% | $0.2130 (−4.61%) |
|
Jun 8, 2026
12d ago
|
Press Release
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 6, 2026
15d ago
|
S-3/A
| $0.2300 $0.2233 | ▲ +2.91% | ▲ +2.62% | $0.2130 (+7.39%) |
|
Jun 5, 2026
15d ago
|
DEFA14A
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 1, 2026
19d ago
|
Press Release
| $0.2530 $0.2610 | ▲ +3.16% | ▲ +3.02% | $0.2130 (−15.81%) |
|
May 26, 2026
25d ago
|
Press Release
| $0.2630 $0.2650 | ▲ +0.76% | ▲ +0.75% | $0.2130 (−19.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access